Stabilization device, system, and methods thereof for integrated catheters

Information

  • Patent Grant
  • 12059536
  • Patent Number
    12,059,536
  • Date Filed
    Thursday, January 30, 2020
    4 years ago
  • Date Issued
    Tuesday, August 13, 2024
    3 months ago
Abstract
Disclosed is a stabilization device and system for stabilizing integrated catheters, and associated methods. The stabilization device can include a platform and a dressing. The platform can have a skin-adhering side configured to stick to a patient's skin and catheter-securing side configured to secure an integrated catheter. The catheter-securing side of the platform can include a contoured recess extending into a body of the platform configured to secure a catheter tube or a hub of the integrated catheter, as well as an extension port of the integrated catheter, a wing assembly of the integrated catheter, or both the extension port and the wing assembly. The dressing can include a transparent polymeric film over a textile pad. The dressing can have a skin-adhering side configured to adhere the dressing to both the integrated catheter secured in the platform and the patient's skin.
Description
BACKGROUND

A peripheral intravenous catheter (“PIVC”) often needs to be prematurely removed from a patient before an intended IV therapy is complete. A primary factor contributing to the need to prematurely remove a PIVC is mechanical phlebitis, which results when the PIVC moves around and irritates the internal anatomy of the patient. Mechanical stabilization of PIVCs has been shown to decrease mechanical phlebitis and increase IV-therapy dwell time. However, existing stabilization devices for such PIVCs are not compatible with integrated PIVCs. Thus, the existing stabilization devices cannot provide the mechanical stabilization needed to reduce mechanical phlebitis and enhance the dwell time needed to complete intended IV therapies with integrated PIVCs. Disclosed herein is a stabilization device and methods thereof for integrated catheters such as integrated PIVCs.


SUMMARY

Disclosed herein is a stabilization system for integrated catheters including, in some embodiments, a platform and a dressing. The platform has a skin-adhering side and catheter-securing side. The catheter-securing side of the platform includes a contoured recess extending into a body of the platform configured to secure a hub of an integrated catheter having an extension port, a wing assembly, or both the extension port and the wing assembly. The dressing is configured to cover the platform together with the integrated catheter secured in the platform over a patient's skin.


In some embodiments, the body of the platform is a foam-like material, the skin-adhering side of the platform has a first adhesive thereon configured to adhere to the patient's skin, and the catheter-securing side of the platform has a second adhesive thereon configured to adhere to the integrated catheter.


In some embodiments, the skin-adhering side and the catheter-securing side of the platform are parallel to each other from a catheter tube-securing front-end portion of the platform to an opposite, back-end portion of the platform.


In some embodiments, the skin-adhering side and the catheter-securing side of the platform are oblique to each other from a catheter tube-securing front-end portion of the platform to an opposite, back-end portion of the platform.


In some embodiments, the front-end portion of the platform includes a cutout extending through the skin-adhering side of the platform configured for accessing a percutaneous insertion site.


In some embodiments, the stabilization system further includes an antimicrobial pad configured for placement around the insertion site, a topical medicament including an antimicrobial agent configured for application around the insertion site, or a skin adhesive configured for sealing the insertion site. The antimicrobial pad is optionally integrated into the body on the skin-adhering side of the platform. The skin adhesive optionally includes a same or different antimicrobial agent than the topical medicament.


In some embodiments, the contoured recess is symmetrical for securing the extension port of the integrated catheter on either a starboard side of the platform or an opposite, port side of the platform.


In some embodiments, the dressing includes a transparent polymeric film over a textile pad. The textile pad has a cutout configured to form a window for viewing a distal end of a catheter tube of the integrated catheter when the dressing covers the platform together with the integrated catheter secured in the platform over the patient's skin.


In some embodiments, the dressing includes a skin-adhering side configured to adhere the dressing to both the integrated catheter secured in the platform and the patient's skin.


In some embodiments, the dressing includes a through hole or slit in at least a starboard side of the dressing or an opposite, port-side of the dressing configured for the extension port or an extension tube of the integrated catheter to pass therethrough.


Also disclosed herein is a stabilization system for integrated catheters including, in some embodiments, a platform and a dressing. The platform has a skin-adhering side configured to stick to a patient's skin and catheter-securing side configured to secure an integrated catheter. The catheter-securing side of the platform includes a contoured recess extending into a body of the platform configured to secure a catheter tube or a hub of the integrated catheter, as well as an extension port of the integrated catheter, a wing assembly of the integrated catheter, or both the extension port and the wing assembly. The dressing includes a transparent polymeric film over a textile pad. The dressing has a skin-adhering side configured to adhere the dressing to both the integrated catheter secured in the platform and the patient's skin.


In some embodiments, the body of the platform is a foam-like material and the contoured recess is symmetrical for securing the extension port of the integrated catheter on either a starboard side of the platform or an opposite, port side of the platform.


In some embodiments, the skin-adhering side and the catheter-securing side of the platform are oblique to each other from a catheter tube-securing front-end portion of the platform to an opposite, back-end portion of the platform.


In some embodiments, the textile pad has a cutout configured to form a window for viewing a distal end of the catheter tube of the integrated catheter when the dressing covers the platform together with the integrated catheter secured in the platform over the patient's skin.


In some embodiments, the dressing includes a through hole or slit in at least a starboard side of the dressing or an opposite, port-side of the dressing configured for the extension port or an extension tube of the integrated catheter to pass therethrough.


In some embodiments, the stabilization system further includes an antimicrobial pad configured for placement around the insertion site, a topical medicament including an antimicrobial agent configured for application around the insertion site, or a skin adhesive configured for sealing the insertion site. The antimicrobial pad is optionally integrated into the body on the skin-adhering side of the platform. The skin adhesive optionally includes a same or different antimicrobial agent than the topical medicament.


Also disclosed herein is a method for stabilizing integrated catheters including, in some embodiments, removing a first adhesive backing from a catheter-securing side of a platform of a stabilization device to expose a contoured recess extending into a body of the platform; securing an integrated catheter in the contoured recess by adhering it thereto, the integrated catheter including a catheter tube, a hub, and an extension port, a wing assembly, or both the extension port and the wing assembly; removing a second adhesive backing from a skin-adhering side of the platform; adhering the platform to a stabilization site on a patient's skin near a percutaneous insertion site; removing a third adhesive backing from a skin-adhering side of a dressing of the stabilization device; and adhering the dressing to the integrated catheter, the platform, and the patient's skin, thereby stabilizing the integrated catheter and decreasing risk of mechanical phlebitis.


In some embodiments, the method further includes viewing a distal end of the catheter tube at the insertion site through a window of the dressing formed by a transparent polymeric film over a cutout in a textile pad.


In some embodiments, the method further includes inserting the extension port or an extension tube of the integrated catheter through a through hole or slit in at least a starboard side of the dressing or an opposite, port-side of the dressing configured and taping the extension tube about the stabilization site to further secure the integrated catheter.


In some embodiments, the method further includes degreasing the patient's skin at the stabilization site with a degreasing wipe before adhering the platform to the patient's skin.


These and other features of the concepts provided herein will become more apparent to those of skill in the art in view of the accompanying drawings and following description, which disclose particular embodiments of such concepts in greater detail.





DRAWINGS


FIG. 1 illustrates a stabilization device for integrated catheters stabilizing an integrated catheter at a stabilization site of a patient adjacent a percutaneous insertion site in accordance with some embodiments.



FIG. 2A illustrates a view of a top of a platform of the stabilization device in accordance with some embodiments.



FIG. 2B illustrates a view of a front of the platform of the stabilization device in accordance with some embodiments.



FIG. 2C illustrates a view of a back of the platform of the stabilization device in accordance with some embodiments.



FIG. 3A illustrates the platform of the stabilization device without an integrated catheter in accordance with some embodiments.



FIG. 3B illustrates the platform of the stabilization device with an integrated catheter in accordance with some embodiments.



FIG. 3C illustrates the platform of the stabilization device with an integrated catheter inserted into a model vein in accordance with some embodiments.



FIG. 4A illustrates the platform of the stabilization device with an extension port of an integrated catheter in a starboard-side recess of the platform in accordance with some embodiments.



FIG. 4B illustrates the platform of the stabilization device with the extension port of the integrated catheter in a port-side recess of the platform in accordance with some embodiments.



FIG. 5 illustrates a skin-adhering side and a catheter-securing side of the platform oblique to each other in accordance with some embodiments.



FIG. 6A illustrates the platform of the stabilization device with a wing-assembly recess of the platform in accordance with some embodiments.



FIG. 6B illustrates the platform of the stabilization device with a wing assembly of an integrated catheter in the wing-assembly recess of the platform in accordance with some embodiments.



FIG. 7A illustrates a first cutout in the platform of the stabilization device for accessing a percutaneous insertion site in accordance with some embodiments.



FIG. 7B illustrates a second cutout in the platform of the stabilization device for accessing a percutaneous insertion site in accordance with some embodiments.



FIG. 7C illustrates a first cutout in the platform of the stabilization device for accessing a percutaneous insertion site in accordance with some embodiments.



FIG. 8 illustrates a stabilization system securing an integrated catheter at a stabilization site of a patient with additional securement about an extension tube of the integrated catheter in accordance with some embodiments.





DESCRIPTION

Before some particular embodiments are disclosed in greater detail, it should be understood that the particular embodiments disclosed herein do not limit the scope of the concepts provided herein. It should also be understood that a particular embodiment disclosed herein can have features that can be readily separated from the particular embodiment and optionally combined with or substituted for features of any of a number of other embodiments disclosed herein.


With respect to terms used herein, it should also be understood the terms are for the purpose of describing some particular embodiments, and the terms do not limit the scope of the concepts provided herein. Ordinal numbers (e.g., first, second, third, etc.) are generally used to distinguish or identify different features or steps in a group of features or steps, and do not supply a serial or numerical limitation. For example, “first,” “second,” and “third” features or steps need not necessarily appear in that order, and the particular embodiments including such features or steps need not necessarily be limited to the three features or steps. Labels such as “left,” “right,” “top,” “bottom,” “front,” “back,” and the like are used for convenience and are not intended to imply, for example, any particular fixed location, orientation, or direction. Instead, such labels are used to reflect, for example, relative location, orientation, or directions. Singular forms of “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.


With respect to “integrated catheter,” an integrated catheter is a one-piece manufacturer-assembled device including a catheter tube fluidly connected to at least one extension tube by way of a hub therebetween. An integrated catheter is different than a non-integrated catheter, which must be assembled by a clinician or the like prior to use.


With respect to “proximal,” as in a “proximal portion” or a “proximal end portion” of, for example, a catheter disclosed herein, “proximal” refers to a portion of the catheter intended to be near a clinician when the catheter is used on a patient. Likewise, a “proximal length” of, for example, the catheter includes a length of the catheter intended to be near the clinician when the catheter is used on the patient. A “proximal end” of, for example, the catheter includes an end of the catheter intended to be near the clinician when the catheter is used on the patient. The proximal portion, the proximal end portion, or the proximal length of the catheter can include the proximal end of the catheter; however, the proximal portion, the proximal end portion, or the proximal length of the catheter need not include the proximal end of the catheter. That is, unless context suggests otherwise, the proximal portion, the proximal end portion, or the proximal length of the catheter is not a terminal portion or terminal length of the catheter.


With respect to “distal,” as in a “distal portion” or a “distal end portion” of, for example, a catheter disclosed herein, “distal” refers to a portion of the catheter intended to be near or in a patient when the catheter is used on the patient. Likewise, a “distal length” of, for example, the catheter includes a length of the catheter intended to be near or in the patient when the catheter is used on the patient. A “distal end” of, for example, the catheter includes an end of the catheter intended to be near or in the patient when the catheter is used on the patient. The distal portion, the distal end portion, or the distal length of the catheter can include the distal end of the catheter; however, the distal portion, the distal end portion, or the distal length of the catheter need not include the distal end of the catheter. That is, unless context suggests otherwise, the distal portion, the distal end portion, or the distal length of the catheter is not a terminal portion or terminal length of the catheter.


With respect to “stabilization site,” a stabilization site is the site at which an integrated catheter is to be stabilized or already stabilized on a patient.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art.


A peripheral intravenous catheter (“PIVC”) often needs to be prematurely removed from a patient before an intended IV therapy is complete. A primary factor contributing to the need to prematurely remove a PIVC is mechanical phlebitis, which results when the PIVC moves around and irritates the internal anatomy of the patient. Mechanical stabilization of PIVCs has been shown to decrease mechanical phlebitis and increase IV-therapy dwell time. However, existing stabilization devices for such PIVCs are not compatible with integrated PIVCs. Thus, the existing stabilization devices cannot provide the mechanical stabilization needed to reduce mechanical phlebitis and enhance the dwell time needed to complete intended IV therapies with integrated PIVCs. Disclosed herein is a stabilization device and methods thereof for integrated catheters such as integrated PIVCs.



FIG. 1 illustrates a stabilization device 100 for integrated catheters stabilizing an integrated catheter at a stabilization site of a patient including a percutaneous insertion site in accordance with some embodiments.


As shown, the stabilization device 100 includes a platform 110 and a dressing 120. For expository expediency, a front or front-end portion of the stabilization device 100 is intended to be placed at or about the insertion site. A back or back-end portion of the stabilization device 100 is opposite the front or front-end portion of the stabilization device 100. The back or back-end portion of the stabilization device 100 is intended to be placed distal to the insertion site. Borrowing from nautical or aeronautical terms for orientation, a starboard side of the stabilization device 100 is the right-hand side of the stabilization device 100 as if standing on the stabilization device 100 and looking toward the front or front-end portion of the stabilization device 100. A port side of the stabilization device 100 is opposite the starboard side of the stabilization device 100. The port side of the stabilization device 100 is the left-hand side of the stabilization device 100 as if standing on the stabilization device 100 and looking toward the front or front-end portion of the stabilization device 100. Such terms are used herein with respect to the platform 110 and the dressing 120 as well.



FIGS. 2A, 2B, and 2C respectively illustrate a view from above the platform 110 of the stabilization device 100, a view from the front of the platform 110 of the stabilization device, and a view from the back of the platform 110 of the stabilization device 100 in accordance with some embodiments. FIG. 3A also illustrates an oblique view of the platform 110 of the stabilization device 100 without an integrated catheter in accordance with some embodiments.


As shown, the platform 110 has a skin-adhering side 114 and a catheter-securing side 112. The skin-adhering side 114 of the platform 110 has a first adhesive thereon configured to adhere to a patient's skin, while the catheter-securing side 112 of the platform 110 has a second adhesive thereon configured to adhere to an integrated catheter. The first and second adhesives can be the same or different.


The catheter-securing side 112 of the platform 110 includes a contoured recess 116 extending into a medically suitable foam-like body of the platform 110, the foam-like body being adaptable to a curved surface such as a patient's hand or arm. The contoured recess 116 is configured to secure a catheter tube or a hub of the integrated catheter having an extension port angled with respect to the hub, a wing assembly, or both the extension port and the wing assembly. For example, a contoured-recess portion 116a is configured to secure the catheter tube or the hub 228 of an integrated catheter, while each portion of the contoured-recess portions 116b and 116c is configured to secure the extension port 229 of an integrated catheter or an extension tube extending therefrom. See FIGS. 3A, 3B, and 3C, which illustrate the platform 110 of the stabilization device 100 with an integrated catheter secured in the contoured recess 116 of the platform 110, the latter figure with the integrated catheter inserted into a model vein.


The contoured recess 116 of the platform 110 is symmetrical for securing the extension port of an integrated catheter or an extension tube extending therefrom on either the starboard side of the platform 110 or the port side of the platform 110 by mere rotation of the integrated catheter along its central axis. See FIGS. 4A and 4B, which respectively illustrate the platform 110 of the stabilization device 100 with an extension port of an integrated catheter in the starboard-side recess 116b of the platform 110 and the port-side recess 116c of the platform 110 in accordance with some embodiments. The symmetrical contoured recess 116 provides orientation options to a clinician when stabilizing an integrated catheter, which include consideration of patient comfort as well.



FIG. 5 illustrates the skin-adhering side 114 and the catheter-securing side 112 of the platform 110 oblique to each other in accordance with some embodiments.


While the skin-adhering side 114 and the catheter-securing side 112 of the platform 110 are parallel to each other from the front-end portion of the platform 110 to the back-end portion of the platform 110 in some embodiments, the skin-adhering side 114 and the catheter-securing side 112 of the platform 110 are oblique to each other in other embodiments. As shown in FIG. 5, the skin-adhering side 114 and the catheter-securing side 112 of the platform 110 can be oblique to each other with an angle θ. The angle θ can range from about 0, when the skin-adhering side 114 and the catheter-securing side 112 are parallel to each other, to about 45°. The angle θ, when less than about 30°, including less than about 15°, such as, less than about 10° (e.g., 8.5°) maintains an appropriate insertion angle for an integrated catheter while minimizing risk of kinking the catheter tube thereof. In addition, such an angle θ minimizes pistoning (e.g., back-and-forth movement within a blood vessel) at the insertion site.



FIG. 6A illustrates the platform 110 of the stabilization device 100 with a wing-assembly recess 116d of the platform 100 in accordance with some embodiments, while FIG. 6B illustrates a wing assembly of an integrated catheter in the wing-assembly recess of the platform in accordance with some embodiments.


As set forth herein, the contoured recess 116 is configured to secure a catheter tube or a hub of an integrated catheter having an extension port angled with respect to the hub, a wing assembly, or both the extension port and the wing assembly. In addition to the contoured-recess portion 116a for the catheter tube or the hub of an integrated catheter and the contoured-recess portions 116b and 116c the extension port of an integrated catheter or an extension tube extending therefrom, the contoured recess 116 can include contoured-recess portion 116d. Contoured-recess portion 116d is configured to secure the wing assembly of an integrated catheter with a wing assembly. Because the wing assembly of integrated catheters with wing assemblies are typically symmetrical, the contoured-recess portion 116d is also symmetrical. Thus, the contoured recess 116 including the contoured-recess portion 116d can remain symmetrical providing the foregoing orientation options to a clinician when stabilizing an integrated catheter, which include consideration of patient comfort as well. In other embodiments, the contoured recess 116 including the contoured-recess portion 116d can be asymmetric providing a specific orientation option to a clinician when stabilizing an integrated catheter.



FIGS. 7A, 7B, and 7C illustrate different cutouts 111 in the platform 110 of the stabilization device 100 for accessing a percutaneous insertion site in accordance with some embodiments.


As shown, the front-end portion of the platform 110 in each figure of FIGS. 7A, 7B, and 7C respectively includes a different cutout 111a, 111b, or 111c extending through the skin-adhering side 114 of the platform 110, each of which is configured for accessing a percutaneous insertion site through the platform 110 or near the front of platform 110. A stabilization system including the stabilization device 100 can further include antimicrobial pad 132 (e.g., BIOPATCH®, GuardIVa®) configured for placement within the cutout 111a and, thus, around the insertion site as shown in FIG. 7A for keeping the insertion site free of infection. The antimicrobial pad 132 is optionally integrated into the body on the skin-adhering side 114 of the platform 110. The stabilization system can further include a topical medicament 134 including an antimicrobial agent configured for application within the cutout 111b and, thus, around the insertion site as shown in FIG. 7B for keeping the insertion site free of infection. The cutout 111b localizes or contains the topical medicament 134, thereby keeping it at the insertion site. The stabilization system can further include a skin adhesive 136 configured for application within the cutout 111c and, thus, around the insertion site as shown in FIG. 7C for sealing the insertion site. The cutout 111c localizes or contains the skin adhesive 136, thereby keeping it at the insertion site. The skin adhesive 136 optionally includes a same or different antimicrobial agent than the topical medicament 134.


As shown in FIG. 1, the dressing 120 is configured to cover the platform 110 together with an integrated catheter secured in the platform 110 over a portion of a patient's skin at the stabilization site. The dressing includes a skin-adhering side configured to adhere the dressing 130 to both an integrated catheter secured in the platform 110 and the patient's skin.


The dressing 120 includes a transparent polymeric film 122 over a textile pad 124. The textile pad 124 has a cutout configured to form a window 126 for viewing a distal end of a catheter tube of an integrated catheter when the catheter tube is at or in the insertion site and the dressing covers the platform together with the integrated catheter secured in the platform at the stabilization site. The textile pad 124 forms a reinforced border around the window 126. While the textile pad 124 can have an additional cutout configured to form an additional window 128 for viewing a hub of an integrated catheter in the platform 110, such an additional window is not a necessity for an integrated catheter like it is for a non-integrated catheter. This is because an integrated catheter is manufacturer assembled to already include a reliable connection between the hub and extension tube of the integrated catheter, so the foregoing connection does not need to be monitored like it does in a non-integrated catheter. That said, the additional window 128 can be useful to a clinician for confirming an integrated catheter is present under the dressing 120.


The dressing 120 includes an opening 129 such as a through hole or a slit in the starboard side of the dressing 120, the opposite, port-side of the dressing 120, or both sides of the dressing 120 configured for an extension port or an extension tube of an integrated catheter to pass therethrough. Without the opening 129, the extension port or the extension tube of such an integrated catheter causes a gap between the dressing 120 and the patient's skin, which can allow microbes to enter the insertion site therethrough. Whether the opening 129 is a through hole or a slit, the dressing 120 is configured to securely wrap around an integrated catheter for both stability and decreased microbial ingress risk. When the opening 129 in the dressing 120 is a slit, the slit can have an angle matching that of the contoured recess 116 in the platform 110 when the contoured recess 116 is configured to secure an extension port of an integrated catheter. The angle can range from about 10° to about 170° (e.g., about 45°) from a longitudinal center line through the dressing.


A length of the dressing 120 from front to back is less than that needed for a dressing for existing stabilization devices for non-integrated catheters. This is because integrated catheters are not typically configured for additional connections in their proximal ends like non-integrated catheters. Integrated catheters already incorporate angled extension ports and extension tubes extending therefrom, which reduces axial footprints of different integrated catheters.



FIG. 8 illustrates a stabilization system including a stabilization device 100 securing an integrated catheter at a stabilization site of a patient with additional securement 142 about an extension tube of the integrated catheter in accordance with some embodiments. As shown, the additional securement 142 can include as a piece of tape configured for securement of an extension tube of an integrated catheter about the stabilization site.


A stabilization system including the stabilization device 100 (i.e., both the platform 110 and the dressing 120), instructions for use of the stabilization device 100, and any one or more additional components selected from the antimicrobial pad 132 (e.g., BIOPATCH®, GuardIVa®), the topical medicament 134, the skin adhesive 136, the additional securement 142, a degreasing wipe, and an antimicrobial wipe can be packaged as a ready-to-use stabilization kit.


A method for stabilizing integrated catheters includes removing a first adhesive backing from the catheter-securing side 112 of the platform 110 of the stabilization device 100 to expose the contoured recess 116 extending into the body of the platform 110; securing an integrated catheter in the contoured recess 116 by adhering it thereto, the integrated catheter including a catheter tube, a hub, and an extension port, a wing assembly, or both the extension port and the wing assembly; removing a second adhesive backing from the skin-adhering side 114 of the platform 110; adhering the platform 110 to a stabilization site on a patient's skin near a percutaneous insertion site; removing a third adhesive backing from the skin-adhering side of the dressing 120 of the stabilization device 120; and adhering the dressing 120 to the integrated catheter, the platform 110, and the patient's skin, thereby stabilizing the integrated catheter, decreasing risk of mechanical phlebitis, and increasing dwell time for the integrated catheter.


The method can further include accessing the insertion site in one or more ways of accessing the insertion site. Accessing the insertion site includes passing the catheter tube of the integrated catheter through any one of the cutouts 111a, 111b, or 111c and into the insertion site. Accessing the insertion site includes placing the antimicrobial pad 132 (e.g., BIOPATCH®, GuardIVa®) around the insertion site to keep the insertion site free of infection as shown in FIG. 7A. Accessing the insertion site includes applying the topical medicament 134 including an antimicrobial agent around the insertion site or sealing the insertion site with the skin adhesive 136 optionally including the same or different antimicrobial agent as shown in FIGS. 7B and 7C. When accessing the insertion site with the topical medicament 134, the cutout 111b localizes or contains the topical medicament 134, thereby keeping it at the insertion site. Likewise, when accessing the insertion site with the skin adhesive 136, the cutout 111c localizes or contains the skin adhesive 136, thereby keeping it at the insertion site. Not only does sealing the insertion site with the skin adhesive 136 prevent microbes from entering the insertion site, but sealing the insertion site has the added effect of further stabilizing an integrated catheter to a patient, thereby decreasing mechanical phlebitis.


The method can further include viewing a distal end of the catheter tube at the insertion site through the window 126 of the dressing 120 formed by the transparent polymeric film 122 over the cutout in the textile pad 124.


The method can further include inserting the extension port or the extension tube of the integrated catheter through the opening 129 (e.g., a through hole or a slit) in at least the starboard side of the dressing or the opposite, port-side of the dressing configured and taping the extension tube with the additional securement 142 (e.g., a piece of tape) about the stabilization site to further secure the integrated catheter.


The method can further include degreasing the patient's skin at the stabilization site with a degreasing wipe before adhering the platform 110 to the patient's skin.


The method can further include disinfecting the patient's skin at the stabilization site with an antimicrobial wipe before adhering the platform 110 to the patient's skin.


While some particular embodiments have been disclosed herein, and while the particular embodiments have been disclosed in some detail, it is not the intention for the particular embodiments to limit the scope of the concepts provided herein. Additional adaptations and/or modifications can appear to those of ordinary skill in the art, and, in broader aspects, these adaptations and/or modifications are encompassed as well. Accordingly, departures may be made from the particular embodiments disclosed herein without departing from the scope of the concepts provided herein.

Claims
  • 1. A stabilization system for an integrated catheter, comprising: a platform having a thickness from a skin-adhering side to a catheter-securing side, wherein the platform is a foam-like material, wherein the skin-adhering side of the platform has a first adhesive thereon configured to adhere to a patient's skin, and wherein the catheter-securing side of the platform has a second adhesive thereon configured to adhere to the integrated catheter, the catheter-securing side of the platform including a contoured recess extending into the platform a distance less than the thickness, the contoured recess comprising: a central channel along a longitudinal axis of the platform;a first angled channel diverging from a first side of the central channel; anda second angled channel diverging from a second side of the central channel, the second angled channel symmetrical with the first angled channel; anda dressing configured to cover the platform together with the integrated catheter secured in the platform over the patient's skin.
  • 2. The stabilization system according to claim 1, wherein the skin-adhering side and a non-recessed catheter-securing side of the platform are parallel to each other from a catheter tube-securing front-end portion of the platform to an opposite, back-end portion of the platform.
  • 3. The stabilization system according to claim 1, wherein the skin-adhering side and a non-recessed catheter-securing side of the platform are oblique to each other from a catheter tube-securing front-end portion of the platform to an opposite, back-end portion of the platform.
  • 4. The stabilization system according to claim 1, further comprising an antimicrobial pad configured for placement around an insertion site, wherein the antimicrobial pad is integrated into the skin-adhering side of the platform.
  • 5. The stabilization system according to claim 1, wherein the dressing includes a transparent polymeric film over a textile pad, the textile pad having a cutout configured to form a window for viewing a distal end of a catheter tube of the integrated catheter when the dressing covers the platform together with the integrated catheter secured in the platform over the patient's skin.
  • 6. The stabilization system according to claim 1, wherein the skin-adhering side is configured to adhere the dressing to both the integrated catheter secured in the platform and the patient's skin.
  • 7. The stabilization system according to claim 1, wherein the dressing includes a through hole or slit in at least a starboard side of the dressing or an opposite, port-side of the dressing configured for an extension port or an extension tube of the integrated catheter to pass therethrough.
  • 8. The stabilization system according to claim 1, further comprising a topical medicament including an antimicrobial agent configured for application around an insertion site, and a skin adhesive configured for sealing the insertion site, wherein the skin adhesive includes the antimicrobial agent in the topical medicament.
  • 9. A stabilization system for an integrated catheter, comprising: a platform having a thickness from a skin-adhering side to a catheter-securing side, wherein the platform is a foam-like material, wherein the skin-adhering side of the platform has a first adhesive thereon configured to adhere to a patient's skin, and wherein the catheter-securing side of the platform has a second adhesive thereon configured to adhere to the integrated catheter, the catheter-securing side of the platform including a contoured recess extending into the platform a distance less than the thickness, the contoured recess comprising: a central channel along a longitudinal axis of the platform;a first angled channel diverging from a first side of the central channel; anda second angled channel diverging from a second side of the central channel, the second angled channel symmetrical with the first angled channel; anda dressing including a transparent polymeric film over a textile pad, the dressing having the skin-adhering side configured to adhere the dressing to both the integrated catheter secured in the platform and the patient's skin.
  • 10. The stabilization system according to claim 9, wherein the skin-adhering side and a non-recessed catheter-securing side of the platform are oblique to each other from a catheter tube-securing front-end portion of the platform to an opposite, back-end portion of the platform.
  • 11. The stabilization system according to claim 9, wherein the textile pad has a cutout configured to form a window for viewing a distal end of a catheter tube of the integrated catheter when the dressing covers the platform together with the integrated catheter secured in the platform over the patient's skin.
  • 12. The stabilization system according to claim 9, wherein the dressing includes a through hole or slit in at least a starboard side of the dressing or an opposite, port-side of the dressing configured for an extension port or an extension tube of the integrated catheter to pass therethrough.
  • 13. The stabilization system according to claim 9, further comprising an antimicrobial pad configured for placement around a percutaneous insertion site, wherein the antimicrobial pad is integrated into the skin-adhering side of the platform.
  • 14. A method for stabilizing integrated catheters, comprising: removing a first adhesive backing from a catheter-securing side of a platform of a stabilization device to expose a contoured recess extending into the platform a distance less than a full thickness of the platform, wherein the platform is a foam-like material, the contoured recess comprising: a central channel along a longitudinal axis of the platform;a first angled channel diverging from a first side of the central channel; anda second angled channel diverging from a second side of the central channel, the second angled channel symmetrical with the first angled channel;securing an integrated catheter in the contoured recess by adhering it thereto, the integrated catheter including a central portion received in the central channel of the contoured recess and a side portion received in one of the first angled channel and the second angled channel;removing a second adhesive backing from a skin-adhering side of the platform;adhering the platform to a stabilization site on a patient's skin near a percutaneous insertion site;removing a third adhesive backing from a skin-adhering side of a dressing of the stabilization device; andadhering the dressing to the integrated catheter, the platform, and the patient's skin, thereby stabilizing the integrated catheter and decreasing risk of mechanical phlebitis.
  • 15. The method according to claim 14, further comprising viewing a distal end of the integrated catheter at the percutaneous insertion site through a window of the dressing formed by a transparent polymeric film over a cutout in a textile pad.
  • 16. The method according to claim 14, further comprising inserting an extension port or an extension tube of the integrated catheter through a through hole or slit in at least a starboard side of the dressing or an opposite, port-side of the dressing and taping the extension tube about the stabilization site to further secure the integrated catheter.
PRIORITY

This application claims the benefit of priority to U.S. Provisional Application No. 62/800,324, filed Feb. 1, 2019, which is incorporated by reference in its entirety into this application.

US Referenced Citations (351)
Number Name Date Kind
2525398 Collins Oct 1950 A
2553961 Rousseau et al. Dec 1950 A
2707953 Ryan May 1955 A
2893671 Flora et al. Jul 1959 A
3046984 Eby Jul 1962 A
3059645 Hasbrouck et al. Oct 1962 A
3064648 Bujan Nov 1962 A
3167072 Stone et al. Jan 1965 A
3204636 Kariher et al. Sep 1965 A
3256880 Caypinar Jun 1966 A
3289671 Troutman et al. Dec 1966 A
3471109 Meyer Oct 1969 A
3482569 Raaelli, Sr. Dec 1969 A
3524443 Batlin Aug 1970 A
3526880 Caypinar Sep 1970 A
3529597 Fuzak Sep 1970 A
3542321 Kahabka Nov 1970 A
3556096 Fuller et al. Jan 1971 A
3602227 Andrew Aug 1971 A
3630195 Santomieri Dec 1971 A
3632071 Cameron et al. Jan 1972 A
3677250 Thomas Jul 1972 A
3700574 Kehr Oct 1972 A
3731684 Spiegel May 1973 A
3766915 Rychlik Oct 1973 A
3834380 Boyd Sep 1974 A
3847370 Engelsher Nov 1974 A
3856020 Kovac Dec 1974 A
3896527 Miller et al. Jul 1975 A
3900026 Wagner Aug 1975 A
3906946 Nordstrom Sep 1975 A
3942228 Buckman et al. Mar 1976 A
3942750 Noorily Mar 1976 A
3973565 Steer Aug 1976 A
3973656 Zumbro Aug 1976 A
3993081 Cussell Nov 1976 A
4020835 Nordstrom et al. May 1977 A
4030540 Roma Jun 1977 A
4057066 Taylor Nov 1977 A
4059105 Cutruzzula et al. Nov 1977 A
4082094 Dailey Apr 1978 A
4114618 Vargas Sep 1978 A
4114626 Beran Sep 1978 A
4129128 McFarlane Dec 1978 A
4133307 Ness Jan 1979 A
4142527 Garcia Mar 1979 A
4149539 Cianci Apr 1979 A
4161177 Fuchs Jul 1979 A
4170995 Levine et al. Oct 1979 A
4193174 Stephens Mar 1980 A
4224937 Gordon Sep 1980 A
4248229 Miller Feb 1981 A
4250880 Gordon Feb 1981 A
4316461 Marais et al. Feb 1982 A
4324236 Gordon et al. Apr 1982 A
4326519 D′Alo et al. Apr 1982 A
4333468 Geist Jun 1982 A
4353369 Muetterties et al. Oct 1982 A
4356599 Larson et al. Nov 1982 A
4362156 Feller, Jr. et al. Dec 1982 A
4389754 Sohma Jun 1983 A
4392853 Muto Jul 1983 A
4392857 Beran Jul 1983 A
4397647 Gordon Aug 1983 A
4405163 Voges et al. Sep 1983 A
4442994 Logsdon Apr 1984 A
4449975 Perry May 1984 A
4453933 Speaker Jun 1984 A
4474559 Steiger Oct 1984 A
4480639 Peterson et al. Nov 1984 A
4484913 Swauger Nov 1984 A
4490141 Lacko et al. Dec 1984 A
4498903 Mathew Feb 1985 A
4500338 Young et al. Feb 1985 A
4502477 Lewis Mar 1985 A
4516293 Beran May 1985 A
4516968 Marshall et al. May 1985 A
4517971 Sorbonne May 1985 A
4533349 Bark Aug 1985 A
4534762 Heyer Aug 1985 A
4563177 Kamen Jan 1986 A
4579120 MacGregor Apr 1986 A
4583976 Ferguson Apr 1986 A
4589702 Bach et al. May 1986 A
4617017 Hubbard et al. Oct 1986 A
4621029 Kawaguchi Nov 1986 A
4623102 Hough, Jr. Nov 1986 A
4633863 Filips et al. Jan 1987 A
4636552 Gay et al. Jan 1987 A
4650473 Bartholomew et al. Mar 1987 A
4659329 Annis Apr 1987 A
4660555 Payton Apr 1987 A
4661110 Fortier et al. Apr 1987 A
4669156 Guido et al. Jun 1987 A
4699616 Nowak et al. Oct 1987 A
4711636 Bierman Dec 1987 A
D293717 Proulx et al. Jan 1988 S
4726716 McGuire Feb 1988 A
4733666 Mercer, Jr. Mar 1988 A
4737143 Russell Apr 1988 A
4742824 Payton et al. May 1988 A
4762513 Choy et al. Aug 1988 A
4775121 Carty Oct 1988 A
4808162 Oliver Feb 1989 A
4823789 Beisang, III Apr 1989 A
4826486 Palsrok et al. May 1989 A
4828549 Kvalo May 1989 A
4838878 Kalt et al. Jun 1989 A
4852844 Villaveces Aug 1989 A
4857058 Payton Aug 1989 A
4863432 Kvalo Sep 1989 A
4869465 Yirmiyahu et al. Sep 1989 A
4874380 Hesketh Oct 1989 A
4880412 Weiss Nov 1989 A
4881705 Kraus Nov 1989 A
4896465 Rhodes et al. Jan 1990 A
4897082 Erskine Jan 1990 A
4898587 Mera Feb 1990 A
4899963 Murphy Feb 1990 A
4919654 Kalt Apr 1990 A
D308576 Iversen Jun 1990 S
4932943 Nowak Jun 1990 A
4944728 Carrell et al. Jul 1990 A
4952207 Lemieux Aug 1990 A
4955864 Hajduch Sep 1990 A
4976700 Tollini Dec 1990 A
4997421 Palsrok et al. Mar 1991 A
5000741 Kalt Mar 1991 A
5037397 Kalt et al. Aug 1991 A
5073166 Parks et al. Dec 1991 A
5073170 Schneider Dec 1991 A
5078731 Hayhurst Jan 1992 A
5084026 Shapiro Jan 1992 A
5098399 Tollini Mar 1992 A
5112313 Sallee May 1992 A
5147322 Bowen et al. Sep 1992 A
5156641 White Oct 1992 A
5163914 Abel Nov 1992 A
5188609 Bayless et al. Feb 1993 A
5192273 Bierman Mar 1993 A
5192274 Bierman Mar 1993 A
5195981 Johnson Mar 1993 A
5224935 Hollands Jul 1993 A
5226892 Boswell Jul 1993 A
5234185 Hoffman et al. Aug 1993 A
5250041 Folden et al. Oct 1993 A
5257768 Juenemann et al. Nov 1993 A
5263939 Wortrich Nov 1993 A
5263943 Vanderbrook Nov 1993 A
5266401 Tollini Nov 1993 A
5267967 Schneider Dec 1993 A
5280866 Ueki Jan 1994 A
5282463 Hammersley Feb 1994 A
5290248 Bierman et al. Mar 1994 A
5292312 Delk et al. Mar 1994 A
5304146 Johnson et al. Apr 1994 A
5306243 Bonaldo Apr 1994 A
D347060 Bierman May 1994 S
5308337 Bingisser May 1994 A
5314411 Bierman et al. May 1994 A
5318546 Bierman Jun 1994 A
5322514 Steube et al. Jun 1994 A
5330438 Gollobin et al. Jul 1994 A
5334186 Alexander Aug 1994 A
5336195 Daneshvar Aug 1994 A
5338308 Wilk Aug 1994 A
5342317 Claywell Aug 1994 A
5344406 Spooner Sep 1994 A
5344414 Lopez et al. Sep 1994 A
5345931 Battaglia, Jr. Sep 1994 A
5346479 Schneider Sep 1994 A
5352211 Merskelly Oct 1994 A
5354282 Bierman Oct 1994 A
5354283 Bark et al. Oct 1994 A
5368575 Chang Nov 1994 A
5374254 Buma Dec 1994 A
5380293 Grant Jan 1995 A
5380294 Persson Jan 1995 A
5380301 Prichard et al. Jan 1995 A
5382239 Orr et al. Jan 1995 A
5382240 Lam Jan 1995 A
5389082 Baugues et al. Feb 1995 A
5395344 Beisang, III et al. Mar 1995 A
5397639 Tollini Mar 1995 A
5398679 Freed Mar 1995 A
5403285 Roberts Apr 1995 A
5413562 Swauger May 1995 A
5443460 Miklusek Aug 1995 A
5449349 Sallee et al. Sep 1995 A
5456671 Bierman Oct 1995 A
5468228 Gebert Nov 1995 A
5468230 Corn Nov 1995 A
5468231 Newman et al. Nov 1995 A
5470321 Forster et al. Nov 1995 A
D364922 Bierman Dec 1995 S
5474572 Hayhurst Dec 1995 A
5484420 Russo Jan 1996 A
5494245 Suzuki et al. Feb 1996 A
5496282 Militzer et al. Mar 1996 A
5496283 Alexander Mar 1996 A
5499976 Dalton Mar 1996 A
5520656 Byrd May 1996 A
5522803 Teissen-Simony Jun 1996 A
5527293 Zamierowski Jun 1996 A
5539020 Bracken et al. Jul 1996 A
5549567 Wolman Aug 1996 A
5551421 Noureldin et al. Sep 1996 A
D375355 Bierman Nov 1996 S
D375356 Bierman Nov 1996 S
5578013 Bierman Nov 1996 A
D377831 Bierman Feb 1997 S
5613655 Marion Mar 1997 A
5616135 Thorne et al. Apr 1997 A
5626565 Landis et al. May 1997 A
5632274 Quedens et al. May 1997 A
5637098 Bierman Jun 1997 A
5643217 Dobkin Jul 1997 A
5653411 Picco et al. Aug 1997 A
5672159 Warrick Sep 1997 A
5676137 Byrd Oct 1997 A
5681290 Alexander Oct 1997 A
5685859 Kornerup Nov 1997 A
5690617 Wright Nov 1997 A
5693032 Bierman Dec 1997 A
5697907 Gaba Dec 1997 A
5702371 Bierman Dec 1997 A
D389911 Bierman Jan 1998 S
5722959 Bierman Mar 1998 A
D393903 Bierman Apr 1998 S
5738660 Luther Apr 1998 A
5755225 Hutson May 1998 A
5776106 Matyas Jul 1998 A
5785201 Bordner et al. Jul 1998 A
5795335 Zinreich Aug 1998 A
5800402 Bierman Sep 1998 A
5810781 Bierman Sep 1998 A
D399954 Bierman Oct 1998 S
5827230 Bierman Oct 1998 A
5827239 Dillon et al. Oct 1998 A
D401329 Bierman Nov 1998 S
5833663 Bierman et al. Nov 1998 A
5846255 Casey Dec 1998 A
D404815 Bierman Jan 1999 S
5855591 Bierman Jan 1999 A
5916199 Miles Jun 1999 A
5921991 Whitehead et al. Jul 1999 A
5922470 Bracken et al. Jul 1999 A
5941263 Bierman Aug 1999 A
5944696 Bayless et al. Aug 1999 A
6001081 Collen Dec 1999 A
6015119 Starchevich Jan 2000 A
6024761 Barone et al. Feb 2000 A
6027480 Davis et al. Feb 2000 A
6054523 Braun et al. Apr 2000 A
D425619 Bierman May 2000 S
6074368 Wright Jun 2000 A
6113577 Hakky et al. Sep 2000 A
6117163 Bierman Sep 2000 A
6131575 Lenker et al. Oct 2000 A
6132398 Bierman Oct 2000 A
6132399 Shultz Oct 2000 A
6206897 Jamiolkowski et al. Mar 2001 B1
6213979 Bierman Apr 2001 B1
6224571 Bierman May 2001 B1
6228064 Abita et al. May 2001 B1
6231548 Bassett May 2001 B1
6258066 Urich Jul 2001 B1
6273873 Fleischer Aug 2001 B1
6274786 Heller Aug 2001 B1
6283945 Bierman Sep 2001 B1
6290676 Bierman Sep 2001 B1
6332874 Eliasen et al. Dec 2001 B1
6361523 Bierman Mar 2002 B1
6387075 Stivland et al. May 2002 B1
6387076 Landuyt May 2002 B1
6413240 Bierman et al. Jul 2002 B1
6419660 Russo Jul 2002 B1
6428514 Goebel et al. Aug 2002 B1
6428515 Bierman et al. Aug 2002 B1
6447485 Bierman Sep 2002 B2
6458104 Gautsche Oct 2002 B2
6491664 Bierman Dec 2002 B2
6500154 Hakky et al. Dec 2002 B1
D470936 Bierman Feb 2003 S
6551285 Bierman Apr 2003 B1
6572588 Bierman et al. Jun 2003 B1
6582403 Bierman et al. Jun 2003 B1
6585703 Kassel et al. Jul 2003 B1
6596402 Soerens et al. Jul 2003 B2
D480144 Adams et al. Sep 2003 S
6663600 Bierman et al. Dec 2003 B2
6685670 Miles et al. Feb 2004 B2
6703120 Ko et al. Mar 2004 B1
D492411 Bierman Jun 2004 S
6770055 Bierman et al. Aug 2004 B2
6786892 Bierman Sep 2004 B2
6796310 Bierman Sep 2004 B2
6829705 Smith Dec 2004 B2
6837875 Bierman Jan 2005 B1
6872194 Doyle et al. Mar 2005 B2
D503977 Bierman Apr 2005 S
6951550 Bierman Oct 2005 B2
6984145 Lim Jan 2006 B1
7018362 Bierman et al. Mar 2006 B2
7074208 Pajunk et al. Jul 2006 B2
7115321 Soerens et al. Oct 2006 B2
7320681 Gillis et al. Jan 2008 B2
7354421 Bierman Apr 2008 B2
7879013 Smith et al. Feb 2011 B2
8052648 Dikeman et al. Nov 2011 B2
8394067 Bracken et al. Mar 2013 B2
8915885 Smith et al. Dec 2014 B2
9616200 Smith et al. Apr 2017 B2
9642987 Bierman et al. May 2017 B2
10322262 Bracken et al. Jun 2019 B2
10561815 Bierman et al. Feb 2020 B2
20020026152 Bierman Feb 2002 A1
20020095119 Bertoch et al. Jul 2002 A1
20020161332 Ramey Oct 2002 A1
20020165493 Bierman Nov 2002 A1
20030125668 Bierman Jul 2003 A1
20040167475 Wright et al. Aug 2004 A1
20050137496 Walsh et al. Jun 2005 A1
20050192539 Bierman et al. Sep 2005 A1
20050205708 Sasaki et al. Sep 2005 A1
20050282977 Stempel et al. Dec 2005 A1
20060025723 Ballarini Feb 2006 A1
20060129103 Bierman et al. Jun 2006 A1
20060233652 Kim et al. Oct 2006 A1
20060289011 Helsel Dec 2006 A1
20070032561 Lin et al. Feb 2007 A1
20070142782 Bierman Jun 2007 A2
20070142784 Dikeman et al. Jun 2007 A1
20070265572 Smith et al. Nov 2007 A1
20070276335 Bierman Nov 2007 A1
20080029476 Ohmi et al. Feb 2008 A1
20080097334 Dikeman et al. Apr 2008 A1
20080249476 Bierman et al. Oct 2008 A1
20090137962 Bracken et al. May 2009 A1
20090149814 Bailey Jun 2009 A1
20100100049 Godfrey Apr 2010 A1
20100298778 Bracken et al. Nov 2010 A1
20110060295 Hen Mar 2011 A1
20130150827 Bracken et al. Jun 2013 A1
20150112270 Smith et al. Apr 2015 A1
20150217088 Zyzelewski Aug 2015 A1
20160193452 Hanson Jul 2016 A1
20170216556 Bierman et al. Aug 2017 A1
20190247623 Helm Aug 2019 A1
20190247625 Bracken et al. Aug 2019 A1
20200171273 Bierman et al. Jun 2020 A1
Foreign Referenced Citations (53)
Number Date Country
995995 Aug 1976 CA
2228747 Feb 1997 CA
2208577 May 1997 CA
2306802 Apr 1999 CA
2310030 May 1999 CA
2281457 Feb 2001 CA
2402507 Sep 2001 CA
2418000 Feb 2002 CA
2483995 Apr 2004 CA
2341297 Apr 1975 DE
3110023 Sep 1982 DE
8811131 Jan 1989 DE
4000380 Aug 1990 DE
29608294 Aug 1996 DE
0064284 Nov 1982 EP
0247590 Dec 1987 EP
0274418 Jul 1988 EP
0356683 Mar 1990 EP
0440101 Aug 1991 EP
0470709 Feb 1992 EP
0597213 May 1994 EP
0931560 Jul 1999 EP
1184139 Jul 1959 FR
2381529 Sep 1978 FR
2722414 Jan 1996 FR
2852520 Sep 2004 FR
2063679 Jun 1981 GB
2086466 May 1982 GB
2219034 Nov 1989 GB
2233902 Jan 1991 GB
2288542 Oct 1995 GB
2312619 Nov 1997 GB
52-004691 Feb 1977 JP
S60-051377 Apr 1985 JP
63501477 Jun 1988 JP
01308572 Dec 1989 JP
1992-051767 Mar 1992 JP
H04-037448 Mar 1992 JP
06-063153 Mar 1994 JP
1995-028563 May 1995 JP
08024344 Jan 1996 JP
H08-257138 Oct 1996 JP
1015663 Jan 2002 NL
8001458 Jul 1980 WO
8502774 Jul 1985 WO
8606641 Nov 1986 WO
9116939 Nov 1991 WO
9219309 Nov 1992 WO
9610435 Apr 1996 WO
9626756 Sep 1996 WO
9853872 Dec 1998 WO
WO-2015035238 Mar 2015 WO
2018138324 Aug 2018 WO
Non-Patent Literature Citations (93)
Entry
Plaintiff's Opening Claim Construction Brief; Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***, Oct. 10, 2008.
Plantiff's Answering Brief in Opposition to Defendant's Motion for Summary Judgement of invalidity; Filed: Oct. 30, 2008; Venetec International Inc. v. Nexus Medical, LLC; USDC, District of Delaware, Civil Action No. 07-cv-0057-MPT. (Oct. 30, 2008).
Rebuttal Expert Report of Dr. Terry N. Layton, Ph.D., Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***, Aug. 29, 2008, 33 pgs.
Request for Inter Partes Reexamination Under 37 C.F.R. 1.913 [filed Jun. 25, 2007]. In re Bierman, USPTO, Reexamination No. 95/000,271.
Search Result, Percufix® Catheter Cuff Kit, downloaded from the Internet on Aug. 15, 2001.
Second Supplemental Complaint [filed Sep. 5, 2007]. Venetec Int'l, Inc. v. Nexus Medical, LLC, USDC D.Del., Case No. 1:07-CV-00057.
Stipulation and Order amending Nexus Medical, LLC's Answer to Complaint and Counterclaim, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-005, 15 pgs. (Jul. 13, 2007).
Third-Party Requester's Response to Patent Owner's Response to Office Action Dated Sep. 21, 2007, Inter Partes Reexamination No. 95/000,271, filed Dec. 21, 2007, 85 pages.
Third-Party Requester's Supplemental Response to Patent Owner's Supplemental Response to Office Action Dated Sep. 21, 2007, Inter Partes Reexamination No. 95/000,271, filed Jan. 22, 2008, 48 pgs.
Transcript of Claim Construction Hearing; Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***, Nov. 21, 2008.
Tri-State Hospital Supply Corporation, Centurion Healthcare Products brochure for HubGuard Catheter Securement (Mar. 3, 2004).
Tri-State Hospital Supply Corporation, Centurion Healthcare Products brochure for IV Start Kits (Sep. 14, 2004).
Tri-State Hospital Supply Corporation, Centurion Healthcare Products brochure for LineGuard J-Loop Securement Device (Nov. 2, 2004).
Tri-State Hospital Supply Corporation, Centurion Healthcare Products brochure for Port Access Trays (Apr. 24, 2003).
Tri-State Hospital Supply Corporation, Centurion Healthcare Products brochure for SorbaView 2000 Window Dressing (Apr. 14, 2004).
Tri-State Hospital Supply Corporation, Centurion Healthcare Products brochure for SorbaView Ultimate Window Dressing (May 7, 2004 and Jun. 22, 2004).
U.S. Appl. No. 12/063,225, filed Feb. 7, 2008 Final Office Action dated Jun. 21, 2016.
U.S. Appl. No. 12/063,225, filed Feb. 7, 2008 Non-Final Office Action dated Nov. 30, 2015.
U.S. Appl. No. 12/063,225, filed Feb. 7, 2008 Notice of Allowance dated Jan. 6, 2017.
U.S. Appl. No. 13/762,803, filed Feb. 8, 2013 Board Decision dated Jul. 3, 2018.
U.S. Appl. No. 13/762,803, filed Feb. 8, 2013 Non-Final Office Action dated Jul. 2, 2015.
U.S. Appl. No. 13/762,803, filed Feb. 8, 2013 Notice of Allowance dated Oct. 10, 2018.
U.S. Appl. No. 13/762,803, filed Feb. 8, 2013 Examiner's Answer dated Dec. 1, 2016.
U.S. Appl. No. 13/762,803, filed Feb. 8, 2013 Final Office Action dated Oct. 30, 2015.
U.S. Appl. No. 14/580,720, filed Dec. 23, 2014 Non-Final Office Action dated Sep. 9, 2016.
U.S. Appl. No. 15/489,594, filed Apr. 17, 2017 Advisory Action dated Jun. 12, 2019.
U.S. Appl. No. 15/489,594, filed Apr. 17, 2017 Final Office Action dated Mar. 7, 2019.
U.S. Appl. No. 15/489,594, filed Apr. 17, 2017 Non-Final Office Action dated Sep. 28, 2018.
U.S. Appl. No. 15/489,594, filed Apr. 17, 2017 Notice of Allowance dated Oct. 1, 2019.
U.S. Appl. No. 90/010,167 filed May 15, 2008 Decision by the Board of Patent Appeals and Interferences (BPSI) in the Ex Parte Reexamination of the '949 patent, dated Aug. 24, 2010.
U.S. Appl. No. 90/010,211, filed Jun. 27, 2008 Decision by the Board of Patent Appeals and Interferences (BPAI) in the Ex Parte Reexamination of the '150 patent, dated Sep. 7, 2010.
Venetec International, Inc.'s Reply to Nexus Medical, LLC's Counterclaim [filed Apr. 11, 2007]. Venetec Int'l, Inc. v. Nexus Medical, LLC, USDC D.Del., Case No. 1:07-CV-00057.
Venetec International, Inc.'s Reply to Nexus Medical, LLC's Counterclaim [filed Aug. 28, 2007]. Venetec Int'l, Inc. v. Nexus Medical, LLC, USDC D.Del., Case No. 1:07-CV-00057.
Venetec International, Inc.'s Reply to Nexus Medical, LLC's Counterclaim [filed Sep. 27, 2007]. Venetec Int'l, Inc. v. Nexus Medical, LLC, USDC D.Del., Case No. 1:07-CV-00057.
Venetec's letter to Judge Thynge dated Sep. 28, 2007, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***, 6 pgs.
Venetec's Motion for Partial Judgement on the Pleadings, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057, 3 pgs. (Sep. 28, 2007).
Venetec's Motion for Partial Judgement on the Pleadings, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057, 34 pgs. (Sep. 28, 2007).
Venetec's Opening Brief in Support of Motion for Partial Judgement on the Pleadings, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-Cv-0057, 34 pgs. (Sep. 28, 2007).
Zefon International printout from www.zefon.com/medical/griplok.htm depicting prior art GRIP-LOK Universal Tubing Securement Device (printed Jun. 20, 2005).
“Occlude”. Merriam-Webster Online Dictionary. <http://www.merriam-webster.com/dictionary/occlude>. Last accessed May 12, 2011.
3M Technical Data Sheet entitled “Adhesive Transfer Tapes with Adhesive 300MP 9692-9695-964” (Sep. 2002).
Bostick Findley Product Data Sheet entitled “4229 Hot Melt Adhesives” (Sep. 2003).
Brief in Support of Nexus Medical, LLC's Motion for Summary Judgement of Noninfringement of the Venetec Patents (Public Redacted Version); Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057, Public version filed Oct. 24, 2008, 158 pgs.
Brief in Support of Nexus Medical, LLC's Motion for Summary Judgement that the Venetec Patents are Invalid; Venetec International Inc. v. Nexus Medical, LLC, USDC, District of Delaware, Civil Action No. 07-cv-0057-MPT. Dated Oct. 10, 2008.
CA 2,619,979 filed Aug. 31, 2006 Office Action dated Oct. 7, 2015.
Civil Docket for Case No. 1:07-CV-00057*** [printed Oct. 22, 2007].
Complaint [dated Jan. 29, 2007]. Venetec Int'l, Inc. v. Nexus Medical, LLC, USDC D.Del., Case No. 1:07-CV-00057.
Declaration of Jennifer C. Bailey in Support of Nexus' Opposition to Venetec's Motion for Partial Judgement on the Pleadings, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057, 31 pgs. (Mar. 15, 2007).
Defendant Nexus Medical, LLC's Objections and Responses to Plantiff Venetec International, Inc's Modified and Supplemental Definitions Set Forth in its First Set of interrogatories to Defendant Nexus Medical, LLC, Venetec International Inc. v. NexusMedical, LLC, U.S. District Court for Delaware, Case No. 07-Cv-0057, 79 pgs. (May 30, 2007).
Defendant Nexus Medical, LLC's Reply to Plantiff's Answering Brief in Opposition to Defendant's Motion for Summary Judgement of Invalidity; Filed: Nov. 10, 2008; Venetec International Inc. v. Nexus Medical, LLC; USDC, District of Delaware, CivilAction No. 07-cv-0057-MPT. (Nov. 10, 2008).
Defendant Nexus Medical, LLC's Reply to Plantiff's Answering Brief in Opposition to Defendant's Motion for Summary Judgement of Noninfringement of the Venetec Patents (Public Version); Venetec International Inc. v. Nexus Medical, LLC, U.S. DistrictCourt for Delaware, Case No. 07-CV-0057, Public version filed Nov. 18, 2008, 27 pgs.
EP 04 07 6329 European Search Report dated Feb. 7, 2005.
EP 06 802789 (PCT/US2006/034203) Supplementary Partial European Search Report dated May 15, 2009.
Expert Report of Julie E. Shomo Regarding Invalidity of the Venetec Patents Pursuant to Rule 26(a)(2)(B), Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***, Jul. 18, 2008, 31pgs.
Expert Report of Marvin Gordon Regarding Invalidity of the Venetec Patents Pursuant to Rule 26(a)(2)(B), Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***, Jul. 18, 2008, 23 pgs.
Expert Report of William H. Hirsch Regarding Invalidity of the Venetec Patents Pursuant to Rule 26(a)(2)(B), Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware. Case No. 07-CV-0057, Jul. 18. 2008, 39 pgs.
First Supplemental Complaint [dated Jul. 24, 2007]. Venetec Int'l, Inc. v. Nexus Medical, LLC, USDC D.Del., Case No. 1:07-CV-00057.
Hi-Tech Products Material Data Sheet entitled “Tricot PSA” (printed prior to Jul. 13, 2006).
Interview Summary in the Ex Parte Reexamination of the '150 patent, U.S. Appl. No. 90/010,211, mailed Dec. 19, 2008, 3 pgs.
Interview Summary in the Ex Parte Reexamination of the '979 patent, U.S. Appl. No. 90/010,167, mailed Dec. 19, 2008, 4 pgs.
Joint Claim Construction Chart; Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***, Oct. 10, 2008, 91 pgs.
Judge Thynge's Order Denying Nexus Motion to Stay Proceedings Pending Reexamination, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV 0057***, 1 pg. (Oct. 12, 2007).
Memorandum Order; Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***, Mar. 28, 2008, 16 pgs.
Nexus Medical , LLC's First Amended Answer and Counterclaim to Venetec International, Inc.'s Second Supplemental Complaint and Counterclaim; Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057, 50pgs. (Mar. 10, 2008).
Nexus Medical LLC's Opening Claim Construction Brief; Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***, Oct. 10, 2008.
Nexus Medical, LLC's Answer to Venetec International, Inc.'s Complaint and Counterclaim [dated Mar. 22, 2007]. Venetec Int'l, Inc. v. Nexus Medical, LLC, USDC D.Del., Case No. 1:07-CV-00057.
Nexus Medical, LLC's Answer to Venetec International, Inc.'s First Supplemental Complaint and Counterclaim [dated Aug. 8, 2007]. Venetec Int'l, Inc. v. Nexus Medical, LLC, USDC D.Del., Case No. 1:07-CV-00057.
Nexus Medical, LLC's Answer to Venetec International, Inc.'s Second Supplemental Complaint and Counterclaim [filed Sep. 19, 2007]. Venetec Int'l, Inc. v. Nexus Medical, LLC, USDC D.Del., Case No. 1:07-CV-00057.
Nexus Medical, LLC's Objections and Responses to Venetec International, Inc's First Set of Interrogatories, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware Case No. 07-CV-0057***. (Aug. 27, 2007).
Nexus' letter to Judge Thynge dated Sep. 27, 2007, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***.
Nexus' Opposition to Venetec's Motion for Partial Judgement on the Pleadings, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057, 28 pgs. (Oct. 15, 2007).
Notice of Assignment of Inter Partes Reexamination Request for the '485 patent, Venetec International Inc. v. Nexus Medical, LLC, U,S. District Court for Delaware, Case No. 07-CV-0057 1 pg. (Jul. 10, 2007).
Notice of Assignment of Reexamination, U.S. Appl. No. 90/010,211, mailed Jul. 7, 2008, 1 pg.
Notice of Reexamination Request Filing Date, U.S. Appl. No. 90/010,211, mailed Jul. 7, 2008, 1 pg.
Office Action in the Ex Parte Reexamination of the '150 patent, U.S. Appl. No. 90/010,211, dated May 11, 2009.
Office Action in the Ex Parte Reexamination of the '979 patent, U.S. Appl. No. 90/010,167, dated May 8, 2009.
Office Action issued to Venetec in the Ex Parte Reexamination of the '150 patent, U.S. Appl. No. 90/010,211, mailed Nov. 7, 2008, 20 pgs.
Office Action issued to Venetec in the Ex Parte Reexamination of the '979 patent, U.S. Appl. No. 90/010,167, mailed Nov. 7, 2008, 21 pgs.
Office Action issued to Venetec in the Inter Partes Reexamination, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***, 23 pgs. (Sep. 21, 2007).
Order Granting Inter Partes Reexamination, Venetec International Inc. v. Nexus Medical, LLC, U.S. District Court for Delaware, Case No. 07-CV-0057***. Sep. 21, 2007.
Order Granting Request for Ex Parte Reexamination of the '150 patent, U.S. Appl. No. 90/010,211, mailed Jul. 29, 2008, 16 pgs.
Order Granting Request for Ex Partes Reexamination, Ex Parte Reexamination of the '979 patent, U.S. Appl. No. 90/010,167, filed Jul. 29, 2008, 14 pgs.
Order Granting Request for Inter Partes Reexamination & Reexamination Non-Final Office Action, Inter Partes Reexamination No. U.S. Appl. No. 95/000,271, filed Sep. 21, 2007,50 pgs.
Patent Owner's Response to Office Action issued to Venetec in the Ex Parte Reexamination of the '150 patent, U.S. Appl. No. 90/010,211, filed Jan. 7, 2009, 36 pgs.
Patent Owner's Response to Office Action issued to Venetec in the Ex Parte Reexamination of the '979 patent, U.S. Appl. No. 90/010,167, Jan. 7, 2009.
Patent Owner's Response to Office Action, Inter Partes Reexamination No. 95/000,271, filed Nov. 21, 2007, 90 pgs.
Patent Owner's Supplemental Response to Office Action, Inter Partes Reexamination No. 95/000,271, filed Sep. 29, 2008, 46 pgs.
Patent Owner's Supplemental Response to Office Action, Inter Partes Reexamination No. 95/000,271, filed Dec. 21, 2007, 46 pgs.
PCT/US06/34203 filed Aug. 31, 2006 International Search Report dated Aug. 7, 2007.
U.S. Appl. No. 16/394,969, filed Apr. 25 2019 Non-Final Office Action dated Aug. 3, 2021.
EP 20747735.7 filed Aug. 18, 2021, Extended European Search Report dated Sep. 6, 2022.
U.S. Appl. No. 16/394,969, filed Apr. 25 2019 Non-Final Office Action dated Jun. 14, 2022.
U.S. Appl. No. 16/783,009, filed Feb. 5, 2020, Non-Final Office Action dated Aug. 4, 2022.
Related Publications (1)
Number Date Country
20200246592 A1 Aug 2020 US
Provisional Applications (1)
Number Date Country
62800324 Feb 2019 US